MedTrace Logo

Effect of Ranolazine on Valvular Disease in Patients With Pacemakers

NCT01979965 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2013-11-08

No results posted yet for this study

Summary

The purpose of this study is to find out whether mitral regurgitation (or a leaky heart valve) caused by ischemic heart disease (decreased blood flow to heart muscle) will improve after administration of ranolazine.

Conditions

  • Ischemic Mitral Regurgitation

Interventions

DRUG

Ranolazine (Active drug)

Ranolazine therapy for three months

DRUG

Placebo

Placebo therapy for three months

Sponsors & Collaborators

  • University Cardiology

    lead OTHER

Principal Investigators

  • Raj Baljepally, MD · University Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2014-05-31
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01979965 on ClinicalTrials.gov